Apeximmune Therapeutics

Private

Burlingame, CaliforniaHealthcare & Life Scienceshttps://apeximmune.com/

Last Round

Series A

Mar 31, 2025

Total Funding Raised

$27.7M

Company Overview

Apeximmune Therapeutics is a biotechnology company that develops novel biologics and therapeutic antibodies designed to modulate the immune system for the treatment of cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverymonoclonal antibodiesimmuno-oncologybiologicsautoimmune diseasestherapeutic antibodiespreclinical researchbioinformaticsimmune checkpoint inhibitorsmulti-specific antibodiesdrug pipelinebiotech startuptarget discoverytherapeutic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Apeximmune Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Apeximmune Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Apeximmune Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Mar 31, 2025
Grant	Jun 1, 2023
Seed	Mar 15, 2021

View all Funding Rounds

Key People

Founding team and executive leadership

Gary Kiang

CFO

Executive Team

Apeximmune Therapeutics Investors

Notable investors and investment history

Apeximmune Therapeutics investors
Investor	Rounds
NIH RADx	Grant
DCI Partners	Series A
TA YA VENTURE HOLDINGS LIMITED	Series A
Hercules Bioventure Partners	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Mar 31, 2025
$21.3M raised in Series A funding.

View all signals

Apeximmune Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Apeximmune Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Apeximmune Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBurlingame, California

Employee Range5

Year Founded2017

Last FundingMar 31, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.